RemeGen Co. Ltd. Class H (9995) Price & Analysis

Compare

5 Followers

9995 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$10.20 - HK$73.20

Previous CloseN/A

Volume1.38M

Average Volume (3M)13.88M

Market Cap

HK$40.71B

Enterprise ValueHK$37.92B

Total Cash (Recent Filing)HK$759.53M

Total Debt (Recent Filing)¥2.67B

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Aug 23, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding208,581,240

10 Day Avg. Volume12,349,910

30 Day Avg. Volume13,876,841

Financial Highlights & Ratios

PEG Ratio-4.07

Price to Book (P/B)20.82

Price to Sales (P/S)0.00

P/FCF Ratio-33.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$53.13

Price Target Upside-22.55% Downside

Rating ConsensusHold

Number of Analyst Covering3

RemeGen Co. Ltd. Class H News

PremiumCompany Announcements

RemeGen Co., Ltd. Announces 2025 H Shareholders Meeting to Discuss Key Governance Changes

5d ago

9995

PremiumCompany Announcements

RemeGen Co., Ltd. Announces Successful AGM and Shareholder Meeting Results

22d ago

9995

PremiumCompany Announcements

RemeGen Partners with Vor Biopharma for Global Expansion of Telitacicept

23d ago

9995

PremiumCompany Announcements

RemeGen Co., Ltd. Completes Successful Placement of H Shares

2M ago

9995

PremiumCompany Announcements

RemeGen’s Telitacicept Gains Approval for Myasthenia Gravis Treatment in China

2M ago

9995

PremiumCompany Announcements

RemeGen Co., Ltd. Announces 2024 AGM with Key Resolutions

2M ago

9995

PremiumCompany Announcements

RemeGen Co., Ltd. Announces Strategic Governance Changes at 2025 Shareholder Meeting

2M ago

9995

PremiumCompany Announcements

RemeGen Co., Ltd. Enhances Governance with New Remuneration Committee

2M ago

9995

See All HK:9995 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

2.14%

Mutual Funds

― Other Institutional Investors

93.85% Public Companies and

Individual Investors

Detailed Ownership Overview >

9995 FAQ

What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?

RemeGen Co. Ltd. Class H lowest stock price was HK$10.20 and its highest was HK$73.20 in the past 12 months.

What is RemeGen Co. Ltd. Class H’s market cap?

RemeGen Co. Ltd. Class H’s market cap is HK$40.71B.

When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?

RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 23, 2025 which is in 35 days.

How were RemeGen Co. Ltd. Class H’s earnings last quarter?

Currently, no data Available

Is RemeGen Co. Ltd. Class H overvalued?

According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does RemeGen Co. Ltd. Class H pay dividends?

RemeGen Co. Ltd. Class H does not currently pay dividends.

What is RemeGen Co. Ltd. Class H’s EPS estimate?

RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does RemeGen Co. Ltd. Class H have?

RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.

What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:9995

RemeGen Co. Ltd. Class H Stock Smart Score

Neutral

Fundamentals

Return on Equity

-56.68%

Trailing 12-Months

Asset Growth

-4.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

RemeGen Co. Ltd. Class H

RemeGen Co. Ltd. Class H (9995) is a prominent biopharmaceutical company based in China, specializing in the discovery, development, and commercialization of innovative biologics for the treatment of cancer, autoimmune, and ophthalmic diseases. The company operates in the healthcare sector, leveraging cutting-edge technology and research capabilities to deliver novel therapeutic solutions. RemeGen is committed to addressing unmet medical needs and improving patient outcomes globally through its robust pipeline of drug candidates.

9995 Stock 12 Month Forecast

Average Price Target

HK$53.13

▼(-22.55%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","64":"HK$64","25.75":"HK$25.8","38.5":"HK$38.5","51.25":"HK$51.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$63.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$53.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$47.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,25.75,38.5,51.25,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Jul<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.7,48.93846153846154,50.17692307692308,51.41538461538462,52.65384615384615,53.892307692307696,55.13076923076923,56.36923076923077,57.607692307692304,58.84615384615385,60.08461538461538,61.323076923076925,62.56153846153846,{"y":63.8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.7,48.11769230769231,48.535384615384615,48.95307692307693,49.370769230769234,49.78846153846154,50.206153846153846,50.62384615384616,51.041538461538465,51.45923076923077,51.87692307692308,52.29461538461539,52.7123076923077,{"y":53.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.7,47.69230769230769,47.684615384615384,47.67692307692308,47.66923076923077,47.66153846153846,47.65384615384615,47.64615384615385,47.63846153846154,47.63076923076923,47.62307692307692,47.61538461538462,47.60769230769231,{"y":47.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.3,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.55,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.65,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >